Ilenia Pellicciotta

Columbia University — United States

Medicine · Health Sciences

14h-index1.6kcitations49works0.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(13), Cancer Cells and Metastasis(12), Pancreatic and Hepatic Oncology Research(11), Immunotherapy and Immune Responses(7), Immune cells in cancer(7)

Publications49 total

CheMo4METPANC: Combination chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) in metastatic treatment-naïve pancreatic adenocarcinoma—Updated clinical and translational findings.
Journal of Clinical Oncology·2025· 1 cited
Figure S1 from A Phase I Study of the Combination of Pexidartinib and Sirolimus to Target Tumor-Associated Macrophages in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors
2024Open Access
Figure S2 from A Phase I Study of the Combination of Pexidartinib and Sirolimus to Target Tumor-Associated Macrophages in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors
2024Open Access
Table S2 from A Phase I Study of the Combination of Pexidartinib and Sirolimus to Target Tumor-Associated Macrophages in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors
2024Open Access
Table S1 from A Phase I Study of the Combination of Pexidartinib and Sirolimus to Target Tumor-Associated Macrophages in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors
2024Open Access
Data from A Phase I Study of the Combination of Pexidartinib and Sirolimus to Target Tumor-Associated Macrophages in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors
2024Open Access
Abstract C023: PDAC tumors from patients treated with combination MEK and autophagy inhibition reveal a treatment sensitive epithelial subtype that is enriched in murine models
Cancer Research·2024
CheMo4METPANC: A randomized phase 2 study with combination chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) compared to chemotherapy alone in metastatic treatment-naïve pancreatic adenocarcinoma.
Journal of Clinical Oncology·2024· 1 cited
AIRPanc: A phase 2, open-label, multicenter, randomized study evaluating neoadjuvant therapy targeting the adenosine immunosuppressive pathway in combination with immune checkpoint blockade and radiation therapy in patients with advanced pancreatic ductal adenocarcinoma who are candidates for surgical resection.
Journal of Clinical Oncology·2024
Abstract C014: CXCR4 inhibition enhances anti-tumor immune response in an <i>ex vivo</i> autologous patient-derived organoids and PBMC model system of pancreatic ductal adenocarcinoma
Cancer Research·2024
Abstract PR05: CheMo4METPANC: Combination Chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) Motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) in METastatic treatment-naïve PANCreatic adenocarcinoma
Cancer Research·2024· 1 cited
Cytotoxic chemotherapy potentiates the immune response and efficacy of combination CXCR4/PD-1 inhibition in models of pancreatic ductal adenocarcinoma
2023· 4 citedOpen Access
MEKiAUTO: A multicenter phase 1 study of combination therapy with the MEK inhibitor, cobimetinib, immune checkpoint blockade, atezolizumab, and the autophagy inhibitor hydroxychloroquine (HCQ) in KRAS-mutated advanced malignancies.
JCO Global Oncology·2023· 2 citedOpen Access
CheMo4METPANC: A phase 2 study with combination chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) Motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) in metastatic treatment-naïve pancreas adenocarcinoma.
Journal of Clinical Oncology·2023· 5 cited
Supplementary Data from Autocrine TGFβ Is a Survival Factor for Monocytes and Drives Immunosuppressive Lineage Commitment
2023Open Access
Data from Autocrine TGFβ Is a Survival Factor for Monocytes and Drives Immunosuppressive Lineage Commitment
2023Open Access
Supplementary Data from Autocrine TGFβ Is a Survival Factor for Monocytes and Drives Immunosuppressive Lineage Commitment
2023Open Access
Data from Autocrine TGFβ Is a Survival Factor for Monocytes and Drives Immunosuppressive Lineage Commitment
2023Open Access
Abstract PR-001: <i>Ex vivo</i> co-culture system with patient-derived organoids to assess CXCR4 inhibitor as an immune modulating agent for human pancreas adenocarcinoma
Cancer Research·2021
A Phase I Study of the Combination of Pexidartinib and Sirolimus to Target Tumor-Associated Macrophages in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors
Clinical Cancer Research·2021· 56 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Gulam A. Manji(18), Mary Helen Barcellos‐Hoff(15), Alexander G. Raufi(13), Shisuo Du(11), Gary K. Schwartz(8), Michael May(8), Renate Parry(7), Shing M. Lee(7), Andrew Chen(7), Raúl Rabadán(7), Naomi Sender(7), Isabelle Ross(7), Chen Hao Lo(6), Brian A. Van Tine(6), Angela C. Hirbe(6), Jaya Sarin Pradhan(6), Sarah Sta Ana(6), Silvia C. Formenti(5), Alba Gonzàlez-Juncà(5), Kyla Driscoll(5)